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Introduction
Epigenetic alterations in acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS) have profound effects on
gene expression and may cause tumor suppressor gene silenc-
ing. A large number of genes are inactivated by hypermethy-
lation of CpG islands in the promoter regions. AML, and
MDS in particular, have extensive aberrant DNA methylation
when compared to normal CD34 positive bone marrow
cells.1 In addition, genome-wide promoter DNA methylation
profiling reveals unique AML subgroups and methylation pat-
terns that are associated with clinical outcome, opening up
new avenues for improved diagnostics and prognostication.2
Since thousands of gene promoters typically undergo DNA
hypermethylation, there is a rationale for using DNA methyl-
transferase inhibitors (DNMTI), which are the first epigeneti-
cally targeted therapies to have shown efficacy in the treat-
ment of MDS and AML.3-5 New drugs that target different epi-
genetic changes, i.e. histone modifications, are under devel-
opment. To offer an individualized therapy, reliable methods
to monitor the efficacy of these novel therapies are needed.
Here, we summarize currently available analyses used for this
purpose and highlight important issues in the choice of
methodology.
Clinical utility of DNA methylation profiling
Over the last couple of decades, many studies have
addressed the use of promoter methylation status of individ-
ual genes for prognostication in myeloid malignancies. Early
studies showed that promoter methylation of the CDKN2B
(p15) gene was associated with disease progression in MDS6,7
and secondary AML,8 and that the CDKN2B promoter was
demethylated during treatment with 5-aza-2’deoxycytidine
(5-aza-CdR).9 However, other studies imply that the clinical
importance of CDKN2B methylation in AML is controver-
sial.10,11 Nonetheless, methylation of different individual genes
and combinations of genes (e.g. CDH1, HIC1, SOCS1,
BCL2L10) were shown to have prognostic impact in MDS
and AML,11-15 increasing expectations that a global screening
approach would improve the clinical utility of DNA methyla-
tion profiling. 
At present, the majority of global methylation profiling
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studies have been performed in AML, with only a few
studies in MDS and chronic myeloproliferative disorders
(CMPD). In AML, several studies have shown a link
between global methylation profiles and distinct chromo-
somal rearrangements such as t(8;21), inv(16), t(15;17),
MLL rearrangements or complex karyotype but, in addi-
tion, new prognostic sub-groups have been identified
based only on their methylation profile.2,11,16,17
Furthermore, recent studies show a correlation between
increased DNA methylation and mutations in enzymes
involved in DNA demethylation (IDH1/2 and TET2),17,18
while another study shows association of TET2mutations
to global hypomethylation.19 Whether this relates to diver-
sities in methodology or biology is a subject for further
investigation. Furthermore, global and gene-specific DNA
methylation levels have been associated with the expres-
sion level of miR29b, a microRNA that targets the 3’UTR
of DNMT3A and 3B, and the Sp1 promoter element of
DNMT1, leading to their downregulation and thus
hypomethylation.20
In MDS, only a few global methylation profiling studies
have been published. In a screen of 807 promoters,
increased methylation was associated with transforma-
tion from low- to high-risk MDS.21 In a different study, a
comprehensive screen of 14,000 promoters revealed that
the basic level of methylation in MDS and secondary AML
is much higher than in de novo AML and in normal CD34+
cells.1 However, so far, no global methylation studies have
addressed the prognostic impact of global methylation
changes in MDS; however, a decrease in methylation was
observed after 5-azacytidine (5-aza-CR) treatment.1 There
have been no global methylation profiling studies in
CMML published so far, and a single study of CMPDs
(polycythemia vera and essential thrombocytosis) did not
reveal differential methylation when compared to normal
controls.22
Accordingly, only limited quantities of global methyla-
tion profiling data in myeloid malignancies are currently
available, and those available are from studies based on
different approaches to methylation detection. Some stud-
ies only analyze methylation at a few CpG sites at the
promoters of selected cancer-associated genes,11,21 while
others also include promoter methylation of genes that
have not previously been implicated in cancer.1,2,10,17,18,22 But
all of the above-mentioned studies focus on a variable
number of selected CpG sites, predominantly at CpG
island promoters. Since recent studies suggest that cyto-
sine methylation outside gene promoters may also be
involved in gene regulation, an unbiased approach may
provide new information.23,24 The current technological
advances allow for a global digital mapping of CpG
methylation that may potentially change our view of the
role of DNA methylation in myeloid malignancies.
However, at this point, the technology and data manage-
ment needed is not to be underestimated. Hopefully, some
of this new knowledge may translate into clinically useful
tools.
Clinical utility of histone modification profiling 
Histone modifications play an important role in deter-
mining cell fate, temporal and special organization of tran-
scription, DNA repair and multiple other cellular func-
tions. In hematologic malignancies, aberrations occur in
writers as well as readers of histone modifications. For
example, mutations of the H3K27me3 histone methyl-
transferase Enhancer of Zeste2 (EZH2) occur in malignant
myeloid disorders.25,26 In addition, in myeloproliferative
syndromes, the frequently mutated JAK2 kinase directly
phosphorylates histones.27 As will be discussed below, the
analyses of histone modifications in clinical specimens are
currently more difficult than the analyses of DNA methy-
lation. Nonetheless, a few studies have been published
that indicate that the profiling of histone modifications in
clinical specimens is feasible.28-31 These experiments were
performed with ChIP-chip procedures. Importantly, recent
improvements in methodology appear to make the use of
primary patient samples more easily accessible. These
procedures will be discussed below.
Methodologies for detection of DNA methylation
Approaches to screen for epigenetic alterations in
myeloid malignancies have mainly taken two directions.
The first approach relies on the evaluation of specific can-
didate cancer genes, frequently representing known tumor
suppressor genes.32 The second strategy employs a global
screen for epigenetic alterations. Although genome-wide
DNA methylation analyses provide new insights into the
methylation pattern of normal cells and cancer cells, there
are limitations to the extent to which genome-wide tech-
niques give full and accurate assessment of the methyla-
tion status of individual genes or CpG sites. As a result,
validation of gene and/or site-specific methylation is usu-
ally recommended as a complement to genome-wide
methods. 
Until now, investigations have been designed to focus
on promoter CpG-island hypermethylation. Recent data
indicate that the methylation status of CpGs outside the
classical CpG-island promoter regions also influence tran-
scriptional regulation. Methylation at the so-called CpG-
island shores,23 in enhancer regions,33 and non-CpG island
promoters24 may also influence gene expression. In addi-
tion, methylation of the repetitive LINE1 sequences has
been used as a proxy marker to monitor the overall
methylation level of cancer epigenomes in AML and
MDS.34-36
Methodologies for global DNA methylation profiling
Currently used methods for global DNA methylation
profiling are listed in Table 1. Methods based on methyla-
tion-sensitive restriction enzymes are limited in their use
due to the location of restriction sites. These approaches,
as for example Restriction Landmark Genomic Scanning
(RLGS)37 or HpaII tiny fragment enrichment by ligation-
mediated PCR (HELP),38 are being replaced more and more
by methods that to a lesser extent pre-select the investi-
gated sequence. Instead, enrichment for methylated DNA
molecules is being accomplished by: i) using enrichment
of methylated DNA sequences by antibodies or proteins
binding methylated DNAs; or ii) methods based on bisul-
fite conversion (Figure 1).
Methods based on enrichment of methylated DNA
One approach uses an anti 5-methyl cytosine (anti-
5mC) antibody for methylome profiling in a technique
called methylated DNA immunoprecipitation (MeDIP).39,40
First, the DNA is sonicated, denatured to single-strand
DNA and then incubated with the anti-5mC antibody.
Alternative methods enrich for methylated DNA by bind-
ing to methyl CpG binding domain proteins (MBDs). This
may be done using MBD3L1, a binding partner of MBD2
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that increases the affinity of MBD2 for methylated DNA
for enrichment (Methylated-CpG island recovery assay
(MIRA).41,42 In an alternative approach, Methyl CpG
immunoprecipitation (MCIp) was developed utilizing
antibody-like recombinant protein (MBD2-Fc) and A-
Sepharose columns for the enrichment of methylated
DNA from genomic DNAs.43 Enriched DNA can either be
labeled and hybridized to whole-genome tiling DNA
arrays (ChIP-on-chip) or analyzed using next generation
sequencing (ChIP-seq; see below)44 (Figure 1A and B).
These protocols allow a comprehensive analysis of the
methylation pattern across the entire genome.
Methods based on bisulfite conversion
At present, most of the commonly used methods for
methylation detection at the single gene and whole
genome levels are based on the initial treatment of the
DNA template by sodium bisulfite. Sodium bisulfite con-
verts C to uracil (U) while it leaves 5mC intact.45 In the
subsequent PCR reactions, U will be amplified as
thymine (T), while the static and unconverted 5mC is
amplified as C. 
One of the most commonly used methods for global
methylation detection uses the bead-based arrays from
Illumina. After bisulfite treatment, the DNA is amplified,
fragmented and hybridized to a large set of short oligonu-
cleotides bound to beads. Each unique genomic region is
represented by two homologous oligonucleotides that
only differ by a specific C/T, and thus gives a relative
measure of the amounts of mC versus C in the template
(Figure 1C). This method has been able to record the
methylation status of approximately 27,500 promoter
island CpGs, but a new chip now enables the recording of
more than 485,000 CpGs, including CpGs at non-CpG
islands, in non-coding regions and at miRNA promoters.46
However, this is still much below the estimated number of
approximately 28 million CpG dinucleotides present in
the whole genome.
Next generation sequencing of the methylome
As for chromatin immunoprecipitated DNA, bisulfite-
converted DNA may be analyzed by next generation
sequencing (NGS). In this process, simultaneous amplifica-
tion of hundreds of sequences from bisulfite-converted or
immunoprecipitated DNA is followed by the sequencing
of up to several hundred million reads. Since the value of
the data is directly proportional to the number of times a
particular genomic region is sequenced in parallel (so-
called coverage), a complete sequencing is currently cost-
prohibitive for studies of multiple samples. Despite these
issues, several groups have recently published whole DNA
methylome data from various hematopoietic cell types
including human pluripotent and differentiated stem
cells,47 and peripheral blood mononuclear cells.48
Reduced Representation Bisulfite Sequencing (RRBS) is
a modification of this technology. The MspI restriction
enzyme that cuts the sequence ‘CCGG’ is used to enrich
for genomic regions that show two of these sites within a
distance of 300 bp or less. As a consequence, CpG islands
and promoters are significantly enriched. The subsequent
sequencing allows quantitative assessment of more than
1×106 independent CpGs.49 This procedure is relatively
cost-effective and allows a higher degree of quantitative
DNA methylation analysis than MeDIP based assays.
Methods for confirmation of methylation status 
at single gene or CpG site level
The methods reviewed below are summarized in Table
K. Grønbæk et al.
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Table 1. Methods for genome-wide methylation profiling.
Methodology                                   Minimum amount    Advantages                                                   Limitations
                                                                 of DNA
Restriction enzyme-based method                                                                                                                               Dependent on distribution of restriction enzyme sites
RLGS                                                                     1.5 mg                                                                                                     Limited coverage of the genome
                                                                                                                                                                                                Low sensitivity
HELP                                                                     10 mg                 Better sensitivity in regions with 
                                                                                                            low CpG island density                                         
Methylated DNA enrichment                                                                                                                                          Lacks full coverage of the epigenome
                                                                                                                                                                                                Dependent on antibody quality
MBD protein enrichment - array                     5 mg                  Good coverage of both CpG islands                  Low sensitivity in low density CpG regions
                                                                                                            and of repetitive elements
MBD protein enrichment - seq                       3 mg                  Best coverage, not dependent                           Is demanding on costs and bioinformatic
                                                                                                            on array design                                                       resources
MeDIP-array                                                         5 mg                                                                                                      Complicated by single stranded DIP
Antibodies against mC/hmC                                 
MeDIP-seq                                                          3-5 mg                                                                                                     Complicated by single stranded DIP
Antibodies against mC/hmC                                  
Bisulfite conversion-based methods                                        Provides information on the
                                                                                                            individual CpG dinucleotides                              
Illumina Array Chip                                          0.5-1 mg               Fast and easy to use in multiple samples        Detects methylation only at the selected CpG sites
Whole genome bisulfite sequencing              5 mg                  High resolution and full coverage with             Is demanding on costs and resources
                                                                                                            whole genome sequencing                                  












2. Most of the currently used methods for DNA methyla-
tion detection at the single gene level rely on the initial
bisulfite conversion of the DNA. This will allow separa-
tion of methylated and unmethylated alleles by two major
mechanisms: i) by specifically amplifying methylated and
unmethylated alleles in two different PCR reactions; or ii)
by a physical separation of a PCR product containing a
mixture of methylated and unmethylated DNA.
Screening for methylation at individual gene promoters
Methylation-specific PCR (MSP) is without doubt the
most frequently used method used to detect methylation
at individual genes. The advantage of MSP is the relatively
simple experimental design and its high sensitivity with a
detection rate of 1 methylated allele in 1,000 unmethylat-
ed alleles.50 However, the major disadvantages are its rela-
tively low specificity, the fact that methylation is only
investigated at the binding sites of the primers, and that it
only detects methylation on a single or a few cytosine
molecules.
More detailed information on the pattern and density of
methylation can be achieved by methylation-specific
melting curve analysis (MS-MCA). This method is based
on the fact that the melting properties of bisulfite-treated
methylated and unmethylated DNA species differ consid-
erably and can, therefore, be separated by melting the dif-
ferent PCR products in a thermal cycler (LightCycler).51,52
The advantages of these methods are their high specifici-
ty, and that they allow semi-quantification of methylation
and resolution of variable methylation patterns at different
molecules in the same specimen.
The MethyLight assay is a TaqMan fluorescence-based,
Monitoring epigenetic changes in MDS
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Figure 1. Methods to detect global DNA methylation. (A) Methylated DNA immunoprecipitation (MeDIP). DNA is sonicated and subsequently
denatured. Single stranded DNA is incubated with antibodies against either methylated (5mC) or hydroxymethylated (5hmC) cytosines fol-
lowed by IP. The IP fraction (enriched for either methylated DNA or hydroxymethylated DNA) can either be labeled and hybridized to whole-
genome tiling arrays or analyzed using next generation sequencing (NGS). (B) Chromatin immunoprecipitation (ChIP) of methylated DNA.
DNA and protein are cross-linked by formalin followed by sonication. DNA is incubated with antibodies or proteins that bind MBDs and pre-
cipitated. The enriched fraction can be analyzed by the same methods as for MeDIP. (C) The DNA is denatured and treated with sodium
bisulfite. Unmethylated cytosine, ‘C’, is converted to uracil, ‘U’, while 5mC or 5hmC are unchanged. In the subsequent amplification, ‘U’ is
amplified as thymine, ‘T’, while the unconverted 5mC or 5hmC are amplified as ‘C’. The amplification products are fragmented and
hybridized to bead-based arrays or analyzed by NGS.
A






























real-time PCR method, which gives a quantitative meas-
ure of the amount of methylated alleles in a mixture with
unmethylated alleles. The average level of methylated
CpG sites in the amplified region is calculated; however,
methylation at individual CpGs is not resolved. The
advantage of this method is its high sensitivity that allows
for detection of one methylated allele among 10,000
unmethylated alleles. Accordingly, MethyLight is efficient
in situations where a limited number of methylated alleles
are detected in a mixture with abundant wild-type DNA,
e.g. in the detection of minimal disease in body fluids such
as sputum, serum and urine. Also, it gives a quantitative
measurement of the amount of methylated alleles. The
disadvantages are the cost and the relative complexity of
the assay.
Quantitative analysis of methylation at individual CpG sites
To obtain detailed information about the methylation
status at every single cytosine in a particular sequence,
bisulfite genomic sequencing has long been the gold stan-
dard. However, methylation detection by pyrosequencing
has recently been accepted as a robust alternative.
In bisulfite genomic sequencing, the bisulfite-converted
DNA sequence is cloned into a plasmid vector in order to
obtain substantial amounts of template for direct sequenc-
ing. In this way, individual alleles are examined for their
specific methylation pattern, and the relative methylation
density of individual cytosines can be estimated.45 The
method is rather laborious, and requires the sequencing of
at least 10 clones per transcript in order to obtain reliable
results.
By contrast, the pyrosequencing technology allows
direct, high-resolution quantification of methylation den-
sity over several consecutive CpG sites. The method is
based on the release of pyrophosphate (PPi, P2O74−) dur-
ing nucleotide extension.53 Typically, protocols recom-
mend that the sequence analyzed should be no longer
than 300 bp; however, in reality, much is resolved by ana-
lyzing sequences no longer than approximately 100 bp.
The advantages of this method are that it is fast and
allows for the detection of 96 samples in a single run, but
in contrast to bisulfite sequencing, methylation is not
resolved at individual alleles.
In the MassARRAY assay, bisulfite-converted DNAs are
amplified with PCR primers that do not discriminate
between methylated or unmethylated sequences. The
resulting PCR product is transcribed into RNA, which is
subsequently cleaved by RNase A. The resulting frag-
ments are then quantitatively tested for their DNA methy-
lation status using matrix-assisted laser desorption ioniza-
tion-time of flight (MALDI-TOF) mass spectrometry.54
Current challenges and novel approaches 
to DNA methylation detection
Methods that distinguish 5-hydroxymethylcytosine (5hmC) 
from 5-methylcytosine (5mC)
The discovery that the frequently mutated TET2 pro-
teins can convert 5mC to 5hmC has challenged the use of
bisulfite-based methods for DNA methylation detec-
tion.55,56 Recent data suggest that TET proteins survey DNA
methylation fidelity at transcription start sites of TET tar-
get genes,57 but at present the abundance and distribution
of 5hmC in MDS and AML, and its exact role in transcrip-
tional regulation, is still a question of debate. However, it
has clearly been shown that bisulfite conversion does not
distinguish 5mC and 5hmC, and that 5hmC containing
regions are poorly amplified by PCR after bisulfite conver-
sion.58 In order to discriminate these two functionally dif-
ferent species, MeDIP-based technologies may be applied.
DNA immunoprecipitation by antibodies specific to 5hmC
and 5mC are followed by PCR for detection of methyla-
tion at the single gene level, and by whole genome
sequencing or array analysis for global methylation detec-
tion. A major obstacle has been the specificity of the anti-
bodies that discriminate 5mC and 5hmC, respectively, but
recently developed alternative methods using enzymatic
and chemical steps to isolate a few or single molecule
hmCs may improve separation of the two species.59
K. Grønbæk et al.
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Table 2. Common methods for determining single gene or CpG site-specific DNA methylation
Method Advantages Limitations
Methylation-specific PCR (MSP) High sensitivity Low specificity
Simple design Detects only methylation of a single or few sites
Fast
Methylation-specific melting curve Higher specificity Relatively simple primer design
analysis (MS-MCA) Semi-quantitative Fast run
MethyLight Very high sensitivity Expensive
Possibility of assessment of MRD Complex primer design
Quantitative
Bisulfite sequencing Gold standard Requires cloning
Individual alleles are investigated Labor-intensive and expensive
Methylation status of each CpG site
Pyrosequencing High resolution quantification of consecutive CpG sites Limited number of consecutive CpG sites
Fast
Multiple samples can be run
MassARRAY High resolution quantification of consecutive CpG sites Resolution of single CpG dinucleotides is
or CpG units sometimes not possible (average methylation
Fast data are given for CpG units)











’Third generation’ sequencing of methylated nucleotides
In the near future, it is envisioned that the cost of
sequencing will be further reduced and the sequencing of
multiple cancer genomes is undertaken in international
consortia. Multiple reads per sequence are required due to
the heterogeneity of prior DNA methylation patterns rep-
resenting a certain sequence. Initial bisulfite treatment or
ChIP would no longer be required as single molecules such
as 5mC and 5hmC can now be detected directly from the
sequencing reads. Novel technologies, such as single mol-
ecule real-time (SMRT) sequencing,60 single-molecule
nanopore sequencing with protein pores,61 or ‘Ion-chip’
technology that directly senses the ions released during
DNA synthesis62 may replace current technologies.
However, for the moment, further documentation of their
power and specificity for methylation detection in clinical
samples is needed. 
Analyses of histone modifications
Posttranslational modifications of the core histones con-
stitute an important part of the epigenetic memory.63 Each
of the core histones is strongly conserved throughout phy-
logenesis and can be modified at multiple residues prima-
rily on its N-terminal tails by multiple enzymes.
Chromatin-IP analysis to identify histone modifications
Histone modification analyses in AML have been
fuelled by the development of ChIP as a suitable method
to identify posttranslational histone modifications at spe-
cific gene promoters. Initially introduced in yeast, this
method has matured over the last ten years and is current-
ly the standard approach.64 ChIP coupled with real-time
PCR allows the identification of histone modification pat-
terns of single promoters and enhancers. The possibility of
covering a region of several kilobases with interspaced
amplicons has enabled researchers to clearly define bind-
ing patterns of transcription factors and of regions of his-
tone modifications with high sensitivity and specificity.65
Nonetheless, this approach still requires an a priori hypoth-
esis of relevant genes and loci. 
The development of unbiased methods, such as ChIP-
chip and ChIP-seq, has vastly improved the potential of
chromatin IP-based analyses of histone modifications.66
The basic principle underlying ChIP-chip and ChIP-seq is
very similar: sheared chromatin with specific histone
modifications is enriched by antibody-based precipitation.
The DNA is subsequently isolated. For ChIP-chip analy-
ses, the usually very small amount of DNA needs to be
amplified and labeled. Finally, a hybridization step onto
specific microarrays is needed. In contrast, for ChIP-seq,
libraries can be generated from small amounts of DNA
available after ChIP and these can be sequenced using
NGS. Nonetheless, there are several critical points that are
common to both procedures. First of all, the antibody used
for ChIP is of vital importance. Specificity of the antibody
needs to be rigorously controlled. For the ChIP procedure
itself, it is necessary to have smaller fragments of chro-
matin with DNA between 400 and 1,000 base pairs long.
The widely used sonication bears the problem that inten-
sity needs to be adjusted for each cell type. It is also pos-
sible to use enzymatic digestion and this can be performed
by several methods. Another important problem and crit-
ical point in the analyses of histone modifications in
leukemia samples relates to the controls used. One control
for changes in leukemia is made up of CD34+ progenitor
cells, but in specific instances it may be feasible to use a
cell population that more closely resembles the trans-
formed cells as control. 
A general problem is the variety of histone modifica-
tions found in vivo and their potential crosstalk. Given that
two alleles are usually present, it might be difficult to
assess whether the histone modifications shown as more
or less well defined peaks are found on the same chromo-
some or on different chromosomes within the same cell.
Sequential ChIP has been described as one solution to this
problem.66,67 In this method, the immunoprecipitated his-
tones are used for a subsequent ChIP to ensure that the
resulting sample is enriched for both modifications on the
same histones. 
Standard chromatin IP methods require high numbers of
cells as starting material. In contrast, most clinical speci-
mens have a rather limited number of cells available. An
important issue is, therefore, to identify the minimum
number of cells that are required for a ChIP-seq experi-
ment. In the last few years, several procedures have been
developed that make use of a limited number of available
cells. In 2007, Attema et al. used about 50,000 purified
stem cells for H3K4 methylation and acetylation analy-
ses.68 Recently, protocols developed by Bradley Bernstein´s
group have developed protocols (so-called nano-ChIP-seq)
in which cell numbers as low as 10,000 can be successfully
used.69-71 These protocols contain significant changes in the
chromatin IP procedure itself but especially also in the
library preparation. Typically, such protocols also involve
a separate amplification step to obtain sufficient DNA. 
In addition to genome-wide histone modification analy-
ses with identified loci, it is also possible to quantify total
histone modification levels. One recent approach used
mass spectrometry-based methods.72 Due to the abun-
dance of histones in normal cells, mass spectrometry can
be used to quantify and identify the posttranslational
modification patterns.73,74 This approach might be espe-
cially interesting for control of epigenetic therapy where-
by global alterations of histone modifications can be ana-
lyzed. Since ChIP-seq and ChIP-chip analyses are unlikely
to be involved in diagnostic procedures in the near future,
it might also be interesting to look at approaches to iden-
tify histone modification changes at a few specific loci.
One possibility here is to couple a chromatin IP with sub-
sequent PCR amplification. However, problems with stan-
dardization and the amount of work involved in this pro-
cedure make such approaches currently unsuitable for use
with clinical specimens on a larger scale. Technologies
such as nano-string might help to improve throughput and
reproducibility.75,76 This technology is based on comple-
mentary sequence-specific probes coupled to biotin and
molecular tags that can be easily identified and quantified.
It is possible that the coupling of this nano-string technol-
ogy to chromatin IP material might help to improve quan-
tification. 
An important problem for ChIP-chip and ChIP-seq
relates to the bioinformatic analyses of the data. Excellent
reviews have been published on this topic.77 The bioinfor-
matic analyses are currently being further improved, espe-
cially for ChIP-seq.
Future developments in histone analysis
The rise of NGS has provided novel opportunities to
decipher epigenetic changes. With the further increase in
sequencing capacity most groups now focus on ChIP-seq
Monitoring epigenetic changes in MDS











of histone modifications in leukemia. But several points
remain to be clarified. Of note, histone modifications as
analyzed by ChIP-based techniques leads to relative
enrichment data only. This is in contrast to DNA methy-
lation studies including methods that allow determination
of the exact methylation status of each CpG dinucleotide.
It is increasingly clear that the histone code is very com-
plex and that the same histone modification might have a
different impact in different regions of the genome.
Finally, only the integration of histone modification pat-
tern data, along with transcription factor binding studies,
RNA-expression and large genome sequencing studies will
reveal the true relevance of these patterns for leukemoge-
nesis.
Technical requirements of methods used to monitor
epigenetic therapy
Since technologies for epigenetic monitoring are con-
stantly evolving, the recommendations for sample han-
dling and requirements may change rapidly. However, for
the time being, a few issues may be worth considering.
Optimal handling of patient material for epigenetic profiling
The correct selection and handling of patient material is
crucial, since the generated data are only as good as the
input material allows. Although new approaches imply
that, for example, formalin-fixed paraffin-embedded
(FFPE) tissue may be used for genome-wide analyses, it is
recommended to use fresh or fresh frozen material in
order to get as few artifacts as possible. For bone marrow
samples with a high fraction of AML blasts, density cen-
trifugation could be used for further enrichment of blasts,
which might be sufficient to define global DNA methyla-
tion patterns and to compare the patterns of a particular
histone modification. In cases in which specific subpopu-
lations need to be analyzed, it might be worthwhile to use
magnetic cell sorting or FACS sorting. For MDS samples,
sorting of the malignant clone might be necessary, but
often difficult. However, using granulocytic fraction may
lead to an enrichment of malignant cells and clearer
results.78
Any method that relies only on the use of DNA is par-
ticularly attractive in a clinical setting due to its stability
that, for example, allows overnight shipment at room
temperature. In contrast, methods involving ChIP typical-
ly require careful and relatively fast handling of material,
and the cells must be analyzed fresh or fresh frozen. In
addition, some analyses may be optimized by immediate
crosslinking of the DNA and chromatin of fresh cells.
Another issue is the amount of material needed which is
typically larger in ChIP-based approaches. However, novel
methods are being developed that allow ChIP experi-
ments with smaller amounts of patient material, as
described above. Requirements for the individual analyses
are listed in Table 1.
Monitoring the effects of epigenetic therapy 
Since the responses to epigenetic therapy are only
observed well after treatment has started, there is a
relentless demand to find markers that allow determina-
tion of treatment efficacy at an early time point. This has
been investigated for 5-aza-CdR9,13 for combination treat-
ment of 5-aza-CR and the selective Class I HDACI
Entinostat,1,79 and for 5-aza-CR and valproic acid
(VPA).80,81 These studies clearly show that DNA methyla-
tion can be reversed by epigenetic therapy at an early
time point during treatment, and that this alteration per-
sists onto the next treatment cycle.1,9 In neither of the
studies could the baseline level of methylation be used to
predict response to epigenetic therapy. However, in the 5-
aza-CdR study, reduced methylation levels over time dur-
ing treatment could predict response. In this study, the
methylation level of 10 selected genes was measured
quantitatively by pyrosequencing. In the 5-aza-
CR/entinostat trial, neither gene re-expression, nor pro-
moter methylation changes of 4 selected genes, as meas-
ured by MSP after the first treatment cycle, could predict
response after 4 cycles.79 These observations may indicate
that quantitative measurements of methylation may be
crucial for the development of markers that can select
patients upfront who will benefit from treatment with
DNMTI. Another explanation might be that the effects of
5-aza-CdR are more directly linked to DNA hypomethy-
lation, whereas methylation-independent effects, such as
RNA damage, may play a larger role in 5-aza-CR mediat-
ed responses.82 However, in the combined 5-aza-CR/VPA
trial, responders showed a relative demethylation and
increased expression of the cell cycle regulator PI-PLCβ1
over time,81 and a recent study suggests that BCL2L10
methylation may be a useful prognostic marker for out-
come in patients treated with 5-aza-CR with and without
the addition of VPA.14
Finally, a special issue relates to the material used when
monitoring the effects of epigenetic therapy; in the
responders the malignant cells may have completely dis-
appeared and molecular investigations are then per-
formed on the residual healthy bone marrow. Thus, sur-
rogate markers in normal tissue may be even more effi-
cient in monitoring effects of epigenetic therapy.
Obviously, these investigations should ideally be per-
formed in large, prospective clinical trials.
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